A Phase 2, Double-Blind, Placebo-Controlled Study to Assess the Effect of Febuxostat 80 mg Once Daily Compared to Placebo on Ambulatory Blood Pressure in Subjects With Hyperuricemia and Hypertension.
Phase of Trial: Phase II
Latest Information Update: 04 Sep 2015
At a glance
- Drugs Febuxostat (Primary)
- Indications Hypertension; Hyperuricaemia
- Focus Therapeutic Use
- Sponsors Takeda
- 04 Sep 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 17 Apr 2013 Planned end date changed from 1 Aug 2013 to 1 Sep 2014 as reported by ClinicalTrials.gov.
- 17 Apr 2013 Status changed from suspended to recruiting as reported by ClinicalTrials.gov.